In the US, Eculizumab (eculizumab systemic) is a member of the drug class selective immunosuppressants and is used to treat Hemolytic Uremic Syndrome, Myasthenia Gravis and Paroxysmal Nocturnal Hemoglobinuria.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Reduction in haemolysis
Immunoglobulin, anit-(human complement C5 α-chain) (human-mouse monoclonal 5G1.1 heavy chain), disulfide with human-mouse monoclonal 5G1.1 light chain, dimer (WHO)
- Eculizumabum (Latin)
- Eculizumab (German)
- Eculizumab (French)
- Eculizumab (Spanish)
- Eculizumab (OS: USAN, BAN)
- AX-451 (IS)
- h5G1.1 (IS)
- h5G1.1VHC+h51.1VLC (IS)
Alexicon, United Kingdom; Alexion, Austria; Alexion, Canada; Alexion, Switzerland; Alexion, Germany; Alexion, Denmark; Alexion, Finland; Alexion, France; Alexion, Luxembourg; Alexion, Netherlands; Alexion, Norway; Alexion, Sweden; Alexion, United States; Alexion Europe SAS, Lithuania; Alexion Pharma Italy, Italy; Alexion Pharma Spain, Spain; GlaxoSmithKline, Latvia; LCA, Belgium
|BAN||British Approved Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Click for further information on drug naming conventions and International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.